Search results
Eli Lilly Is Trading At A Record High Ahead Of A Key FDA Meeting — Is It A Buy?
Investor's Business Daily· 15 hours agoShares of companies working on treatments for metabolic dysfunction-associated steatohepatitis, or...
Up 400% In 3 Years, Eli Lilly Stock Just Keeps Giving
Forbes· 1 day agoEli Lilly stock (NYSE: LLY) has seen phenomenal gains of 400% from levels of $170 in early 2021 to...
Is This Trend a Threat to Eli Lilly's Weight Loss Drug Dominance?
Motley Fool via Yahoo Finance· 23 hours agoImage source: Getty Images. Mounjaro and Zepbound First, a bit of background on Lilly's products and...
Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO
Zacks via Yahoo Finance· 2 days agoIts stock rose 273.8% in the last three years. Lilly’s revenue growth is being driven by higher...
Eli Lilly details NASH effects of weight loss drug (NYSE:LLY)
Seeking Alpha· 3 days agoEli Lilly (LLY) posts detailed mid-stage results highlighting the benefits of its weight loss drug...
...Therapeutics' Obesity Candidate Is ' Very Competitive' To EliLilly's Orforglipron, Analyst Says -...
Benzinga· 5 days agoStructure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290,...
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks via Yahoo Finance· 18 hours agoCEO Sundar Pichai. Ashkenazi has been Lilly’s CFO since 2021. In the last three years of her tenure...
Is Eli Lilly and Company (LLY) A Good “Quality Stock” to Buy Now?
Insider Monkey via Yahoo Finance· 1 day agoWe recently compiled the list of the 13 Best Quality Stocks To Buy according to the hedge funds...
Eli Lilly's Wegovy rival Zepbound will help make weight-loss drug market worth $130 billion by 2030,...
Business Insider via Yahoo Finance· 6 days agoWhen it reported first-quarter results in April, Lilly cited strong demand for Zepbound and other...
Eli Lilly’s Obesity Drug Crunch Shows Signs of Easing in Japan
Bloomberg· 2 days agoHave a confidential tip for our reporters? Eli Lilly & Co.’s hefty investment in expanding...